Roche Pharma teams up with 10 Govt Hospitals to power up clinical trial capacities in India
New Delhi: Roche Pharma has announced that it has joined hands with ten government hospitals to strengthen India's clinical trial ecosystem. Under this initiative, nearly 400 professionals—including investigators, ethics committee members, and other resources—have been trained as per global Good Clinical Practice (GCP) standards, PTI reported. Neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME), are two leading causes of vision loss worldwide. Vabysmo is the dual-pathway-inhibitor that uniquely targets and inhibits two disease pathways linked to a number of vision threatening retinal conditions. It neutralises both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) which are key proteins involved in the development and progression of retinal conditions, contributing to vision loss by destabilising blood vessels in the eye.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!